Shefali Agarwal
Chief Executive Officer bij VALERIO THERAPEUTICS
Vermogen: 76 997 $ op 31-03-2024
Profiel
Shefali Agarwal is currently the Chairman, President & Chief Executive Officer at Valerio Therapeutics SA, an Independent Director at Fate Therapeutics, Inc., and an Independent Director at Gritstone bio, Inc. She previously served as the Chief Medical Officer at SQZ Biotechnologies Co. from 2017 to 2018 and as the Executive VP, Chief Medical & Development Officer at Epizyme, Inc. from 2018 to 2022.
Dr. Agarwal holds a graduate degree from The Johns Hopkins University, a doctorate degree from Karnataka University, and a graduate degree from Merrick School of Business.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
FATE THERAPEUTICS, INC.
0.01% | 06-06-2023 | 10 490 ( 0.01% ) | 76 997 $ | 31-03-2024 |
GRITSTONE BIO, INC.
-.--% | 16-06-2023 | 0 ( -.--% ) | - $ | 31-03-2024 |
Actieve functies van Shefali Agarwal
| Bedrijven | Functie | Begin |
|---|---|---|
| FATE THERAPEUTICS, INC. | Director/Board Member | 15-07-2019 |
| GRITSTONE BIO, INC. | Director/Board Member | 01-06-2021 |
| VALERIO THERAPEUTICS | Chief Executive Officer | 06-04-2022 |
Eerdere bekende functies van Shefali Agarwal
| Bedrijven | Functie | Einde |
|---|---|---|
| EPIZYME, INC. | Chief Tech/Sci/R&D Officer | 06-04-2022 |
| SQZ BIOTECHNOLOGIES COMPANY | Chief Tech/Sci/R&D Officer | 01-05-2018 |
Opleiding van Shefali Agarwal
| The Johns Hopkins University | Graduate Degree |
| Karnataka University | Doctorate Degree |
| Merrick School of Business | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 4 |
|---|---|
| SQZ BIOTECHNOLOGIES COMPANY | Health Technology |
| VALERIO THERAPEUTICS | Health Technology |
| FATE THERAPEUTICS, INC. | Health Technology |
| GRITSTONE BIO, INC. | Health Technology |
| Bedrijven in privébezit | 1 |
|---|---|
Epizyme, Inc.
 Epizyme, Inc. BiotechnologyHealth Technology Epizyme, Inc. is a clinical-stage biopharmaceutical company. The firm engages in the discovery, development, and commercialization of novel epigenetic medicines for cancer and other diseases. Its product pipeline is lead by, tazemetostat which targets Non-Hodgkin Lymphoma, molecularly defined solid tumors, non-small-cell lung carcinoma, molecularly targeted tumors, and ovarian cancer. The firm also develops pinometostat for genetically defined acute leukemia, and EZM8266 for sickle cell disease. The company was founded by Robert Horvitz and Zhang Yi on November 1, 2007 and is headquartered in Cambridge, MA. | Health Technology |
